Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-05, Stock:LLY, The news for the past five days is as follows:
2018-08-28: NEWS1: Novartis’s Quarterly Revenue Trend in Q2 2018.NEWS2: 25 Dividend Stocks That Analysts Love the Most.NEWS3: Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study.NEWS4: Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study.NEWS5: Novartis’s Valuation in August.NEWS6: Pfizer&apos;s Tafamidis Fails to Impress in Cardiomyopathy Study.
2018-08-29: NEWS1: 25 Dividend Stocks That Analysts Love the Most.NEWS2: 25 Dividend Stocks That Analysts Love the Most.NEWS3: Novartis' Tafinlar/Mekinist Combo Gets EU Nod for 3rd Disease.NEWS4: Novartis' Tafinlar/Mekinist Combo Gets EU Nod for 3rd Disease.
2018-08-30: NEWS1: Anne White Promoted to President of Lilly Oncology.NEWS2: Pfizer’s Stock Performance in August.NEWS3: AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon.NEWS4: AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon.NEWS5: Estimates and Recommendations for Novartis in August.
2018-08-31: NEWS1: How Eli Lilly’s Business Segments Performed in Q2 2018.NEWS2: Glaxo's Asthma Drug Gets EU Nod for Pediatric Population.NEWS3: Glaxo's Asthma Drug Gets EU Nod for Pediatric Population.NEWS4: Analyzing Eli Lilly’s Q2 2018 Revenue Trend.NEWS5: Glaxo&apos;s Asthma Drug Gets EU Nod for Pediatric Population.NEWS6: Eli Lilly’s Valuation on August 30.NEWS7: Biotech Stocks Facing FDA Decision In September.NEWS8: Biotech Stocks Facing FDA Decision In September.
2018-09-04: NEWS1: Insurance tactic drags down U.S. drug prices in 2nd qtr -analyst.NEWS2: Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised).NEWS3: Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised).NEWS4: Insurance tactic drags down U.S. drug prices in 2nd quarter -analyst.NEWS5: AstraZeneca Up This Year So Far on Favorable Pipeline Updates.NEWS6: AstraZeneca Up This Year So Far on Favorable Pipeline Updates.NEWS7: Better Buy: Pfizer Inc. vs. Eli Lilly and Company.NEWS8: Better Buy: Pfizer Inc. vs. Eli Lilly and Company.NEWS9: WisdomTree U.S. LargeCap Dividend Fund -- Insider Buying Index Registering 12.1%.NEWS10: WisdomTree U.S. LargeCap Dividend Fund -- Insider Buying Index Registering 12.1%.NEWS11: How Eli Lilly’s Elanco Performed in Q2 2018.NEWS12: AstraZeneca Up This Year So Far on Favorable Pipeline Updates.NEWS13: Better Buy: Pfizer Inc. vs. Eli Lilly and Company.NEWS14: A Look at Eli Lilly’s Neuroscience Products in Q2 2018.

Answer: Rise